Cell Therapy News 21.16 May 4, 2020 | |
| |
TOP STORYScientists uncovered the previously inaccessible kinetics and fate choices of transplanted hematopoietic stem cells in myeloablated recipients at early stage. [Nat Cell Biol] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Engineered Niches Support the Development of Human Dendritic Cells in Humanized Mice Engraftment of engineered mesenchymal stem cells together with CD34+ hematopoietic stem and progenitor cells created an in vivo synthetic niche in the dermis of immunodeficient mice driving the differentiation of classical dendritic cells (DCs) and CD123+AXL+CD327+ pre/AS-DCs. [Nat Commun] Full Article Cellular Backpacks for Macrophage Immunotherapy Scientists report an engineered particle referred to as a “backpack” that could robustly adhere to macrophage surfaces and regulate cellular phenotypes in vivo. [Sci Adv] Full Article The authors successfully generated anti-CD117 CAR T-cells from healthy donors and acute myeloid leukemia (AML) patients. Anti-CD117 CAR T-cells efficiently targeted healthy and leukemic CD117-positive cells in vitro. In mice xenografted with healthy human hematopoiesis, they eliminated CD117-expressing, but not CD117-negative human cells. [Leukemia] Abstract CRISPR/Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreich’s Ataxia Investigators optimized the gene editing approach in hematopoietic stem and progenitor cells isolated from healthy and Friedreich’s ataxia patients’ peripheral blood, and demonstrated normal hematopoiesis of gene-edited cells in vitro and in vivo. [Mol Ther Methods Clin Dev] Abstract | Full Article | Graphical Abstract A Soluble Endoplasmic Reticulum Factor as Regenerative Therapy for Wolfram Syndrome Researchers showed that mesencephalic astrocyte-derived neurotrophic factor (MANF), a neurotrophic factor secreted from endoplasmic reticulum (ER) stressed cells, prevented ER stress-mediated β cell death and enhanced β cell proliferation in cell and mouse models of Wolfram syndrome, a prototype of ER disorders. [Lab Invest] Full Article Investigators found that the human β-defensin 3 gene-modified human periodontal ligament cells presented with high levels of osteogenesis-related gene expression and calcium deposition. [Int J Oral Sci] Full Article Immunostimulatory Oncolytic Virotherapy for Multiple Myeloma Targeting 4-1BB and/or CD40 Scientists proposed and evaluated immunostimulatory lokon oncolytic adenoviruses for multiple myeloma treatment. [Cancer Gene Ther] Full Article Microfluidic Synthesis of Injectable Angiogenic Microgels When encapsulated with cells, angiogenic microgels improved wound healing and liver regeneration, compared with non-angiogenic or acellular microgels. [Cell Rep Phys Sci] Full Article | Graphical Abstract Subscribe to one of our other 19 science newsletters such as Mesenchymal Cell News & ESC & iPSC News. | |
| |
REVIEWSCRISPR/Cas9 and prime gene editing to correct mutations in hematopoietic stem cells of β-thalassemia patients has been considered a novel therapeutic approach for effective hemoglobin production. However, genome-editing technologies, along with all advantages, have shown some disadvantages due to either random insertions or deletions at the target site of edition or non-specific targeting in genome. [Gene Ther] Abstract Visit our reviews page to see a complete list of reviews in the cell therapy research field. | |
| |
INDUSTRY NEWSUM Offers Stem Cells to Treat COVID-19 Patients with Life-Threatening Respiratory Infections For COVID-19 patients in severe respiratory distress, the University of Miami Miller School of Medicine (UM) now offers access to mesenchymal stem cell treatments that may help fight the characteristic inflammation that accompanies the viral infection. [University of Miami Miller School of Medicine] Press Release Adverum Biotechnologies, Inc. announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase I clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD). [Adverum Biotechnologies, Inc] Press Release Editas Medicine, Inc. announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatment of solid tumor cancers. [Editas Medicine, Inc.] Press Release Marker Therapeutics, Inc. announced that the FDA Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen-specific T cell product for the treatment of patients with acute myeloid leukemia, following allogeneic stem cell transplant. [Marker Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSAs COVID-19 Forces Conferences Online, Scientists Discover Upsides of Virtual Format As the novel coronavirus outbreak shutters businesses and disrupts everyday life for billions around the globe, massive annual conferences and small society meetings alike have moved online. The new format poses numerous technical and organizational challenges, but it also offers opportunities- for reaching wider audiences, reducing the carbon footprint of meeting travel, and improving diversity and equity. [ScienceInsider] Editorial The Pandemic’s Effects on Recruiting International STEM Trainees Pandemic-related concerns that have arisen for science trainees—shuttered labs, research and education delays, anxiety—are applicable across the board. But international graduate students and postdocs face a suite of unique challenges that raise uncertainty about recruiting and supporting this critical group of researchers in the future. [The Scientist] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Principal Scientist – Human iPSC Gene Engineering (Empyrean Therapeutics Ltd) Lab Director – Cancer Immunotherapy (Vrije Universiteit Brussel) Postdoctoral Fellow – Cancer Drug Discovery (Uniformed Services University of Health Sciences) Scientist – Cancer Immunotherapy (Vrije Universiteit Brussel) Postdoctoral Associate – Diabetes (University of Miami Health System) Team Leaders – Stem Cell Biology (RIKEN Center for Biosystems Dynamics Research) Professorship – Biological Therapies of the Inner Ear (Hannover Medical School) Group leaders – Cancer Biology (Institute of Pharmacology and Structural Biology) Scientist – Cancer Immunotherapy (Lund University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|